Last updated: March 2, 2026
What is the Scope of Patent RS52911?
Patent RS52911 is related to a novel formulation or method in the pharmaceutical domain, specifically for a drug marketed in Serbia. The scope encompasses claims that define the boundaries of the patent’s protection, typically focusing on:
- The composition of matter or formulation specifics.
- The method of manufacturing or preparing the drug.
- Specific excipients or delivery mechanisms.
- Use claims related to therapeutic indications.
Exact details on the scope are defined by the claims, which detail technical features. RS52911 appears to cover a formulation or utilization of a medicinal compound, potentially with novel properties or application.
How Are the Claims Structured?
The patent document generally includes independent claims and dependent claims.
- Independent Claims: Define broad technical features of the invention, such as a specific compound, formulation, or method.
- Dependent Claims: Narrow the scope by adding specific features, such as particular dosages, administration routes, or excipients.
Typical Claims Analysis (Based on Standard Practice)
| Claim Type |
Likely Content |
Example Features |
| Independent |
Composition or method |
A pharmaceutical formulation comprising compound X and excipient Y for treating condition Z. |
| Dependent |
Specific variants |
The formulation of claim 1, wherein the excipient is cellulose. |
| Additional |
Use claims |
A method of treating condition Z using the formulation of claim 1. |
Without access to the original wording, the typical scope around drug patents like RS52911 covers formulation specifics, therapeutic use, and manufacturing methods.
Patent Landscape for Serbia and International Context
Regional Patent Environment
Serbia, as a signatory to the European Patent Convention (EPC), aligns its patent laws with broader European standards. Patent RS52911 is filed under the Serbian Patent Office, which recognizes patents for up to 20 years from the application date, subject to annual fees.
International Patent Family
Most medicinal patents are part of a broader patent family filed under the Patent Cooperation Treaty (PCT), allowing extending patent protection internationally.
- Potential PCT Filing: If RS52911 belongs to an international patent family, similar patents exist in markets such as the European Patent Office (EPO), US, China, and other jurisdictions.
- Patent Family Members: These typically aim for broad territorial coverage, covering major pharmaceutical markets.
Competitor and Landscape Analysis
- The patent landscape around this drug likely includes prior art based on similar formulations, therapeutic methods, or chemical compounds.
- Known patent classifications (IPC codes) could include A61K (preparations for medical, dental, or botanical purposes) and C07D (heterocyclic compounds), depending on the compound involved.
Patent Citations
Patents citing RS52911 (forward citations) indicate the influence or scope of the patent within the technological space. Prior art references (backward citations) highlight the landscape influence and overlaps.
Patent Expiry and Freedom-to-Operate
- Typical patent life: 20 years from filing.
- Check the filing date for RS52911 (not provided) to estimate expiry.
- Overlapping patents or published applications could restrict commercialization or require licensing.
Conclusion
RS52911 protects a specific drug formulation or method, with claims structured to prevent competitors from producing similar products without infringement. The patent landscape involves a network of national, regional, and international patents with potential for broad geographical coverage. The main strategic considerations involve patent expiry, potential overlaps, and current legal enforceability.
Key Takeaways
- The patent’s scope hinges on its claims relating to formulation, method, or use.
- The patent landscape extends beyond Serbia via PCT filings and regional patents.
- Competitor analysis is required to assess infringement risks and licensing opportunities.
- The patent likely expires 20 years from the filing date, with regulatory data influencing market exclusivity.
FAQs
Q1: How do I determine the exact claims of RS52911?
Access the Serbian Patent Office database or official patent documents to review the published patent text, specifically the claims section.
Q2: Can RS52911 be challenged or invalidated?
Yes. If prior art demonstrates that the claims lack novelty or inventive step, third parties can file a legal challenge during patent prosecution or via post-grant procedures.
Q3: Are there international equivalents of RS52911?
Likely, if a PCT application was filed. Search patent databases like WIPO Patentscope or EPO Espacenet for family members.
Q4: How does patent RS52911 affect generic drug entry?
The patent can block generic formulations until expiry or licensing unless challenged successfully.
Q5: What strategies can extend patent protection?
Filing secondary or follow-up patents around formulations, delivery systems, or therapeutic methods before the original patent lapses.
References
- Serbian Intellectual Property Office. (2021). Patent Law of the Republic of Serbia.
- World Intellectual Property Organization. (2022). WIPO Patent Landscape Reports.
- European Patent Office. (2022). Patent Classification and Search.
- WIPO. (2022). PCT Applicant's Guide.
- USPTO. (2022). Patent Search Tools and Resources.
